Label: TOPICAL CLEANSER - benzoyl peroxide soap
- NDC Code(s): 67405-435-06, 67405-435-12
- Packager: Harris Pharmaceutical, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: unapproved drug other
If you are a consumer or patient please visit this version.
- INSTRUCTIONS FOR USE
Benzoyl Peroxide Topical Cleanser 6% is a topical, gel-based, benzoyl peroxide containing preparation for use in the treatment of acne vulgaris. Benzoyl peroxide is an oxidizing agent that possesses antibacterial properties and is classified as a keratolytic. Benzoyl peroxide (C14H10O4) is represented by the following chemical structure:
Benzoyl Peroxide Topical Cleanser 6% contains Benzoyl Peroxide USP 6% as the active ingredient, in a vehicle consisting of: carbomer interpolymer type A NF, cetyl alcohol NF, disodium oleamido MEA-sulfosuccinate, edetate disodium USP, glycerin USP, glyceryl stearate/PEG-100 stearate, laureth-12, magnesium aluminum silicate NF, propylene glycol USP, purified water, sodium coco-sulfate, sodium lauroamphoacetate, xanthan gum NF.
- CLINICAL PHARMACOLOGY
The mechanism of action of benzoyl peroxide is not totally understood but its antibacterial activity against Propionibacterium acnes is thought to be a major mode of action. In addition, patients treated with benzoyl peroxide show a reduction in lipids and free fatty acids, and mild desquamation (drying and peeling activity) with simultaneous reduction in comedones and acne lesions. Little is known about the percutaneous penetration, metabolism, and excretion of benzoyl peroxide, although it has been shown that benzoyl peroxide absorbed by the skin is metabolized to benzoic acid and then excreted as benzoate in the urine. There is no evidence of systemic toxicity caused by benzoyl peroxide in humans.
- INDICATIONS & USAGE
INDICATIONS AND USAGE:Close
Benzoyl Peroxide Topical Cleanser 6% is indicated for the topical treatment of acne vulgaris.
This preparation is contraindicated in patients with a history of hypersensitivity to any of its components.
When using this product, avoid unnecessary sun exposure and use a sunscreen.
- GENERAL PRECAUTIONS
For external use only. If severe irritation develops, discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes.
- INFORMATION FOR PATIENTS
Information for Patients:Close
Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. Contact with any colored material (including hair and fabric) may result in bleaching or discoloration. If excessive irritation develops, discontinue use and consult your physician.
- CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY
Carcinogenesis, Mutagenesis, Impairment of Fertility:Close
Data from several studies employing a strain of mice that are highly susceptible to developing cancer suggest that benzoyl peroxide acts as a tumor promoter. The clinical significance of these findings to humans is unknown. Benzoyl peroxide has not been found to be mutagenic (Ames Test) and there are no published data indicating it impairs fertility.
Pregnancy Category C: Animal reproduction studies have not been conducted with benzoyl peroxide. It is not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can effect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed. There are no available data on the effect of benzoyl peroxide on the later growth, development and functional maturation of the unborn child.
- NURSING MOTHERS
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be
exercised when benzoyl peroxide is administered to a nursing woman.
- PEDIATRIC USE
Safety and effectiveness in children have not been established.
- ADVERSE REACTIONS
Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.
If excessive scaling, erythema or edema occurs, the use of these preparations should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used. After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.
- DOSAGE & ADMINISTRATION
DOSAGE AND ADMINISTRATION:
Wash affected areas once or twice daily, or as directed by your dermatologist. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.
- HOW SUPPLIED
Benzoyl Peroxide Topical Cleanser 6% – 6 oz.(170.3 g) bottle, NDC 67405-435-06
Benzoyl Peroxide Topical Cleanser6% – 12oz.(340.2g) bottle, NDC 67405-435-12Close
- STORAGE AND HANDLING
Store at 15°–25°C(59°–77°F).Close
- PRINCIPAL DISPLAY PANEL
HARRIS Pharmaceutical, Inc.
Ft. Myers, FL
Montreal,QC H4S 1X6
- INGREDIENTS AND APPEARANCE
benzoyl peroxide soap
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67405-435 Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength BENZOYL PEROXIDE (UNII: W9WZN9A0GM) (BENZOYL PEROXIDE - UNII:W9WZN9A0GM) BENZOYL PEROXIDE 60 mg in 1 g Inactive Ingredients Ingredient Name Strength CARBOMER INTERPOLYMER TYPE A (55000 CPS) (UNII: 59TL3WG5CO) CETYL ALCOHOL (UNII: 936JST6JCN) DISODIUM OLEAMIDO MEA-SULFOSUCCINATE (UNII: 5M1101WGSY) EDETATE DISODIUM (UNII: 7FLD91C86K) GLYCERIN (UNII: PDC6A3C0OX) GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4) POLYOXYL 100 STEARATE (UNII: YD01N1999R) LAURETH-12 (UNII: OAH19558U1) MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) WATER (UNII: 059QF0KO0R) SODIUM COCO-SULFATE (UNII: 3599J29ANH) SODIUM LAUROAMPHOACETATE (UNII: SLK428451L) XANTHAN GUM (UNII: TTV12P4NEE) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:67405-435-06 170.3 g in 1 BOTTLE 2 NDC:67405-435-12 340.2 g in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 11/18/2010 Labeler - Harris Pharmaceutical, Inc. (617204370) Registrant - Groupe PARIMA, Inc. (252437850) Establishment Name Address ID/FEI Business Operations Groupe PARIMA, Inc. 252437850 manufacture